E
40.09
-1.26 (-3.05%)
| Previous Close | 41.35 |
| Open | 41.32 |
| Volume | 2,211,802 |
| Avg. Volume (3M) | 2,880,443 |
| Market Cap | 10,792,329,216 |
| Price / Earnings (TTM) | 19.27 |
| Price / Earnings (Forward) | 14.99 |
| Price / Sales | 5.37 |
| Price / Book | 5.47 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | 27.99% |
| Operating Margin (TTM) | 33.64% |
| Diluted EPS (TTM) | 2.19 |
| Quarterly Revenue Growth (YOY) | 30.60% |
| Quarterly Earnings Growth (YOY) | 327.70% |
| Total Debt/Equity (MRQ) | 8.78% |
| Current Ratio (MRQ) | 3.50 |
| Operating Cash Flow (TTM) | 842.59 M |
| Levered Free Cash Flow (TTM) | 559.13 M |
| Return on Assets (TTM) | 18.05% |
| Return on Equity (TTM) | 30.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Exelixis, Inc. | Bearish | Bullish |
AIStockmoo Score
-0.5
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -3.5 |
| Average | -0.50 |
|
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.20% |
| % Held by Institutions | 93.99% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Morgan Stanley, 24.72%) | Buy |
| 50.00 (JMP Securities, 24.72%) | Buy | |
| Median | 45.50 (13.50%) | |
| Low | 38.00 (UBS, -5.21%) | Hold |
| Average | 45.10 (12.50%) | |
| Total | 6 Buy, 4 Hold | |
| Avg. Price @ Call | 38.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 17 Sep 2025 | 40.00 (-0.22%) | Hold | 40.44 |
| Goldman Sachs | 17 Sep 2025 | 47.00 (17.24%) | Buy | 40.44 |
| Morgan Stanley | 17 Sep 2025 | 50.00 (24.72%) | Buy | 40.44 |
| 29 Jul 2025 | 46.00 (14.74%) | Buy | 36.94 | |
| HC Wainwright & Co. | 12 Aug 2025 | 46.00 (14.74%) | Buy | 37.95 |
| UBS | 30 Jul 2025 | 38.00 (-5.21%) | Hold | 36.85 |
| Guggenheim | 29 Jul 2025 | 45.00 (12.25%) | Buy | 36.94 |
| JMP Securities | 29 Jul 2025 | 50.00 (24.72%) | Buy | 36.94 |
| RBC Capital | 29 Jul 2025 | 45.00 (12.25%) | Hold | 36.94 |
| Stifel | 29 Jul 2025 | 41.00 (2.27%) | Hold | 36.94 |
| Truist Securities | 29 Jul 2025 | 49.00 (22.22%) | Buy | 36.94 |
| 15 Jul 2025 | 56.00 (39.69%) | Buy | 44.06 | |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Aug 2025 | Announcement | Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development |
| 27 Aug 2025 | Announcement | Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September |
| 28 Jul 2025 | Announcement | Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update |
| 24 Jul 2025 | Announcement | Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |